BOSTON, MA, USA & Hamburg, Germany -- September 13, 2005 -- PerkinElmer, Inc. (NYSE: PKI), a global leader in health sciences, and Eppendorf AG, a leading supplier of systems and research tools for the biotechnology industry worldwide, announced today the signing of a co-marketing agreement to jointly promote microarray technology that combines Eppendorf’s DualChip™ content arrays with PerkinElmer’s ScanArray™ GX Microarray Analysis System. The announcement was made at the Chips to Hits industry event being held September 12-14, 2005, in Boston.

The combination of the novel DualChip technology, consisting of 2 identical arrays on a single slide, and the user-friendly scanning protocols of ScanArray GX provides a complete solution, from array processing to data analysis. The PerkinElmer/Eppendorf microarray solution is ideal for a wide range of applications, including medical, clinical and biotechnology research.

“Our scanners, combined with the optimized protocols for Eppendorf’s new chip technologies, will deliver reliability and simplicity to customers,” said Peter Coggins, PhD., president, PerkinElmer Life and Analytical Sciences. “For each DualChip, Eppendorf will provide exact protocols to allow customers to set-up and optimize their assays on PerkinElmer scanners, thereby offering considerable advantages and significantly increasing efficiency.”

“With PerkinElmer and Eppendorf’s combined array expertise, committed scientists can now use an array as a personal tool that fits the budget,” stated Dr. Thomas Kolzau, director of the Microarray Systems Product Group at Eppendorf AG. Only recently Eppendorf AG had been conferred the 2005 Frost & Sullivan Technology Innovation Award in recognition for its unique contribution by proactively leveraging its new DualChip Microarray technology to molecular technologies towards possible drug discovery and clinical research applications. According to Frost & Sullivan’s findings, microarrays have been widely demonstrated to empower researchers working in drug discovery and clinical research through the expression profiling method.

Factors Affecting Future Performance
This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that relate to prospective events or developments, including, without limitation, all projections of future financial results, are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," “projects,” “forecasts,” "will" and similar expressions are intended to identify forward-looking statements. There are a number of important risk factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including, without limitation, economic and geopolitical forces that may limit any continued or expected economic or end market strengthening or recoveries, risks related to our failure to introduce new products in a timely manner, the impact of our debt on our cash flow and investment opportunities, our ability to comply with financial covenants contained in our credit agreements and debt instruments, cyclical downturns continuing to affect several of the industries into which we sell our products, our ability to adjust our operations to address unexpected changes, our ability to execute acquisitions and license technologies and successfully integrate acquired businesses and licensed technologies into our existing business, the loss of any of our licenses that may require us to stop selling products or lose competitive advantage, competition, regulatory compliance, regulatory changes, our failure to obtain and enforce intellectual property protection, our defense of third party claims of patent infringement and our ability to realize the full value of our intangible assets, as well as other factors which we describe under the caption "Forward-Looking Information and Factors Affecting Future Performance" in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q, each on file with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

About Eppendorf AG
Eppendorf AG is based in Hamburg, Germany. In the 2004 financial year, Eppendorf employed 1,748 people worldwide and achieved sales of 287 million Euro (approx. 345 million US Dollars) with an operative result (EBIT) of 40.1 million Euro (approx. 48 million US Dollars).